• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Our Products
    • Restoret
  • Team
EyeBio

EyeBio

  • Business Development
  • News
  • Contact

Back to Team

Jonathon Dines, Ph.D.

Finance Director

LinkedIn

Jon joined EyeBio as Finance Director in March 2023, bringing over 15 years of experience across R&D, finance, and investment in the biotech sector.

Originally trained as a medicinal chemist, Jon worked as a Senior Scientist in Drug Discovery at Evotec, generating multiple patents and contributing to a variety of publications in the field of inflammation. In 2011 Jon moved into a finance role and qualified as a chartered accountant in PwC’s financial services division. He has since worked in the biotech venture capital sector, joining SV Health Investors in 2015. Jon performed a range of roles at SV, supporting creation of, and serving as Head of Finance for, the £250m Dementia Discovery Fund. During this time Jon increasingly performed supporting and non-executive roles for several early-stage UK biotechs, and joined Enara Bio full-time as Finance Director in 2020.

Jon holds an MSci in Biochemistry and Biological Chemistry from the University of Nottingham, a Ph.D. in Medicinal Chemistry from UCL, and is a Chartered Accountant (ACA),

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Our Products
    • Restoret
  • Team
  • Business Development
  • News
  • Contact